Current Gene Therapy
Title:Neuroprotective Gene Therapy for Parkinson’s Disease
Volume: 2 Issue: 4
Author(s): L. Tenenbaum, A. Chtarto, E. Lehtonen, D. Blum, V. Baekelandt, T. Velu, J. Brotchi and M. Levivier
Affiliation:
Export Options
About this article
Cite this article as:
Tenenbaum L., Chtarto A., Lehtonen E., Blum D., Baekelandt V., Velu T., Brotchi J. and Levivier M., Neuroprotective Gene Therapy for Parkinson’s Disease, Current Gene Therapy 2002; 2 (4) . https://dx.doi.org/10.2174/1566523023347661
DOI https://dx.doi.org/10.2174/1566523023347661 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Liquid Crystal Nanodispersions Enable the Cutaneous Delivery of Photosensitizer for Topical PDT: Fluorescence Microscopy Study of Skin Penetration
Current Nanoscience Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Ion Channels and Epilepsy
Current Pharmaceutical Design Image Fusion of Diagnostic Ultrasound with Other Modalities
Current Medical Imaging Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Current Approaches for the Treatment with Thyroid Hormone Analogs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids
Current Immunology Reviews (Discontinued) Rate Limiting Steps of AAV Transduction and Implications for Human Gene Therapy
Current Gene Therapy Age and Dose-Dependent Effects of Alpha-Lipoic Acid on Human Microtubule- Associated Protein Tau-Induced Endoplasmic Reticulum Unfolded Protein Response: Implications for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Organoselenium Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Natural Polyphenols in the Treatment of Alzheimer’s Disease
Current Drug Targets Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Calcium Channels and Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery